Founded in 2011 by Paul A. Liberti, PhD, BioMagnetic Solutions is a worldwide pioneer & leader for immuno-magnetic separation (IMS) systems for: immuno-oncology cell therapy, rare cell isolation and circulating tumor cells (CTC).

BioMagnetic Solutions (BMS) is developing cellular isolation systems with our 5th-gen novel ferrite magnetic nanoparticles for: cancer diagnostics, immuno-oncology therapies and other medical applications where exquisite immuno-magnetic cellular isolation is tantamount.

BMS is the successor biotech to BioMagnetic Solutions CEO/CSO Paul A. Liberti, Ph.D.’s Immunicon company where he pioneered CTC isolation with the FDA-approved Prix-Galien award-winning CellSearch© system now owned & marketed by Johnson & Johnson’s Janssen Oncology unit.

BMS is developing a very novel front-end isolation system for circulating tumor cells (CTC) using our proprietary 5th-generation ferrite-based nanoparticles. BMS’ system utilizes principles of magnetic manipulation not previously applied to cells.

In addition to its CTC and rare cell applications, BMS’ platforms are applicable to large-scale clinical cell separation and immunotherapy for CAR-T/Byte/TCR/TIL & CD34+ cord blood applications.

BMS partners with world-class biopharma firms for IO cell therapy, rare cell & immuno-magnetic cell isolation systems leveraging its cutting-edge IMS IP. BMS’ academic research roots & commitment to serving life science researchers run deep. BMS serves the research community via select collaborations with top researchers.

BMS brings 30+ cutting-edge years of R&D, problem-solving, IP & innovation to the design, synthesis & manufacture of Ferrofluids & Immuno-Magnetic Separation Innovator and inventor: 43 U.S. patents. Formulated Immunicon's (NASDAQ: IMMC) patent strategy for rare cell analysis and cancer diagnostics, leading to CellSearch product suite. Won 5 patent dispute issues with USPTO. Successfully defended Immunicon in the European Patent Office against major European Pharmaceutical firms and strategized successful outcome of 5 way interference on MRI contrast agents. CellSearch was awarded the international 2009 Prix Galen as the best medical technology of the year.

President, CEO and CSO
BioMagnetic Solutions
July 2012 – Present
State College, Pennsylvania Area
Development of a very novel front-end isolation system for circulating tumor cells (CTC) that leverages BioMagnetic Solutions' 5th generation ferrofluids for exquisite cell separation.

President
BioMolecular Solutions, a Consulting Firm
2000 – Present (14 years)
Providing various consulting service to startup and emerging technology companies. From a technological side, I consult in the following areas: ferrofluids,magnetic particles, high gradient magnetics, cell separations, protein chemistry, polyelectrolyte chemistry and prototype design. On the business side, I provide consulting services for startups and 2nd round financing, patents and patent strategy, business development and particularly strategic relationship strategies.

Founder, CEO & President
Immunicon Corporation
February 1983 – 2000 (17 years)
Founder, CEO and Principal Scientist/CSO of Immunicon in 1983. Responsible for raising $2.5 million in startup funding, I played the principal role in bringing an additional $27 million of licensing, R&D and venture financing into Immunicon from 1982 to 2000. Principal inventor of Immunicon's biologically-active nanomagnetic ferrofluids (FFs), high-gradient magnetic devices and cell separation technologies. Laid the strategy for the Immunicon's IP estate and played a key role in business development that led to major partnerships in immunodiagnostics, MRI contrast agents, therapeutic cell separation, rare cell analysis and a marketing partnership with J&J's Ortho Diagnostics, Ortho Clinical Diagnostics. In 2000, J&J created its Veridex cancer diagnostics division (now Janssen Diagnostics) to market Immunicon's ferrofluids in the CellSearch suite of circulating tumor cell (CTC) cancer diagnostics that remains the only FDA-approved test for circulating tumor cells.

Consulting Firm/President
Immunochemical Associates
1978 – 1988 (10 years)
Provided technical consulting on monoclonal antibody technology (manufacture of fragments for different subtypes) and on the isolation and manufacture of components of the Complement system. Additionally small lot manufacture of specialty immunochemical components.

Professor of Biochemistry and Immunology
Thomas Jefferson University's Jefferson Medical College
1968 – 1985 (17 years)
Principal investigator on an NIH funded program during his academic career. Director of an Immunlogy Post Doctoral Training program (National Institute of Allergy and Infectious Diseases). The Liberti laboratory was considered one of the Centers of Excellence in Immunochemistry and on the structure and mechanism of the first component of complement.